Base de datos : ins
Búsqueda : DISPONIBILIDAD BIOLOGICA [Descritor de assunto]
Referencias encontradas : 3 [refinar]
Mostrando: 1 .. 3   en el formato [Detallado]

página 1 de 1

  1 / 3 ins  
              next record last record
selecciona
para imprimir
Id:8395
Autor:Welling, Peter; Tse, Francis; Dighe, Shrikant
Título:Pharmaceutical bioequivalence^ien ..-
Fuente:New York; Marcel Dekker,INC; 1991. 467 p. ^btab, ^bilus, ^bgraf.
Descriptores:Equivalencia Terapéutica
Tecnología Farmacéutica
Disponibilidad Biológica
Localización:PE14.4; CH-00323


  2 / 3 ins  
              first record previous record next record last record
selecciona
para imprimir
Id:8307
Autor:Silva, L. C; Simões, I. G; Lerner, F. E; Belém, G. R; De Moraes, M. E; De Nucci, G
Título:Comparative bioavailability of two different diclofenac formulations in healthy volunteers^ien ..-
Fuente:Aulendorf; Editio Cantor; 1999. 920-924 p. ^bgraf, ^btab.
Resumen:The aim of the study was to assess the bioequivalence of two different diclofenac (CAS 15307-86-5) formulations (diclofenac free acid suspension as test formulation and diclofenac resinate suspension, Cataflam, as reference formulation) in 24 healthy volunteers. After an overnight fast, the volunteers received a single oral dose (50 mg) of each formulation, following an open, randomized, two-period crossover design, with a fourteen-day washout interval between doses. Serum samples were obtained over a 24-h interval post-dosing, and were analysed for their diclofenac content by HPLC-UV. No adverse effect was reported for any of the formulations administered. Geometric mean test/reference individual ratios were: 92.8 percent for AUC(0-24 h), 93.2 ercent for AUC(0-infinity), 117.2 percent for Cmax, 131.0 percent for Ke and 76.2 percent for T1/2. The variability of Cmax parameter expressed as CV was greater than 25 percent . Since the 90 percent CI for AUC(0-24 h) mean ratio were within the 80-125 percent interval proposed by the Food and Drug Administration, it can be concluded that diclofenac free acid formulation is bioequivalent to diclofenac resinate formulation for the extent of absorption. Since the European Community Agency accepts a 90 percent CI for Cmax of 70-143 percent , it can be concluded that diclofenac free acid formulation is bioequivalent to diclofenac resinate formulation for both the rate and the extent of absorption after single dose administration. (AU)^ien.
Descriptores:Diclofenaco
Disponibilidad Biológica
Límites:Humanos
Localización:PE14.1


  3 / 3 ins  
              first record previous record
selecciona
para imprimir
Id:8305
Autor:Magosso, E; Yuen, K. H; Choy, W. P; Ng, B. H; Ur-Rahman, N; Wong, J. W; Ling, S. S
Título:Comparative bioavailability study of a generic sustained release diclofenac sodium tablet^ien ..-
Fuente:Malaysia; Malaysian Medical Association; 2004. 352-356 p. ^bgraf, ^btab.
Resumen:The bioavailability of a generic diclofenac sodium sustained release tablet preparation (Zolterol, SR) was compared with the innovator product, Voltaren, SR. Twelve healthy adult male volunteers participated in the study, which was conducted according to a randomized, two-way crossover design with a wash out period of one week. The bioavailability of diclofenac was compared using the parameters area under the plasma concentration-time curve (AUC(0-infinity)), peak plasma concentration (Cmax) and time to reach peak plasma concentration (Tmax). No statistically significant difference was observed for both logarithmically transformed AUC(0-infinity), Cmax values and Tmax value of the two preparations. (AU)^ien.
Descriptores:Diclofenaco
Equivalencia Terapéutica
Disponibilidad Biológica
Límites:Humanos
Localización:PE14.1



página 1 de 1
   


Refinar la búsqueda
  Base de datos : ins Formulario avanzado   
Buscar por : Formulario libre   

    Buscar en el campo  
1  
2
3
 
           



Search engine: iAH v2.6.1 powered by WWWISIS

BIREME/OPS/OMS - Centro Latinoamericano y del Caribe de Información en Ciencias de la Salud